HomeComparePXXLF vs PLD

PXXLF vs PLD: Dividend Comparison 2026

PXXLF yields 769.23% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PXXLF wins by $1993573.27M in total portfolio value
10 years
PXXLF
PXXLF
● Live price
769.23%
Share price
$0.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1993579.18M
Annual income
$1,587,586,259,724.30
Full PXXLF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — PXXLF vs PLD

📍 PXXLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPXXLFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PXXLF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PXXLF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PXXLF
Annual income on $10K today (after 15% tax)
$65,384.62/yr
After 10yr DRIP, annual income (after tax)
$1,349,448,320,765.66/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PXXLF beats the other by $1,349,444,282,649.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PXXLF + PLD for your $10,000?

PXXLF: 50%PLD: 50%
100% PLD50/50100% PXXLF
Portfolio after 10yr
$996792.54M
Annual income
$793,795,505,224.74/yr
Blended yield
79.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

PXXLF
No analyst data
Altman Z
-38.9
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PXXLF buys
0
PLD buys
0
No recent congressional trades found for PXXLF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPXXLFPLD
Forward yield769.23%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$1993579.18M$5.91M
Annual income after 10y$1,587,586,259,724.30$4,750,725.19
Total dividends collected$1961258.26M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PXXLF vs PLD ($10,000, DRIP)

YearPXXLF PortfolioPXXLF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$87,623$76,923.08$11,241$540.96+$76.4KPXXLF
2$723,685$629,928.66$13,019$991.13+$710.7KPXXLF
3$5,636,611$4,862,267.81$15,801$1,870.97+$5.62MPXXLF
4$41,424,664$35,393,490.07$20,609$3,701.21+$41.40MPXXLF
5$287,421,912$243,097,521.69$29,919$7,867.97+$287.39MPXXLF
6$1,883,909,531$1,576,368,085.04$50,631$18,617.74+$1883.86MPXXLF
7$11,672,156,017$9,656,372,818.42$105,528$51,352.20+$11672.05MPXXLF
8$68,403,300,373$55,914,093,435.45$287,364$174,449.42+$68403.01MPXXLF
9$379,432,636,011$306,241,104,611.84$1,081,760$774,280.77+$379431.55MPXXLF
10$1,993,579,180,256$1,587,586,259,724.30$5,908,209$4,750,725.19+$1993573.27MPXXLF

PXXLF vs PLD: Complete Analysis 2026

PXXLFStock

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Full PXXLF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this PXXLF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PXXLF vs SCHDPXXLF vs JEPIPXXLF vs OPXXLF vs KOPXXLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.